Tianda Pharmaceuticals Dirección

Dirección controles de criterios 3/4

El CEO de Tianda Pharmaceuticals es Alan Fang, nombrado en Feb 2017, tiene una permanencia de 7.75 años. posee directamente un 56.72% de las acciones de la empresa, con un valor de HK$225.62M. La antigüedad media del equipo directivo y de la junta directiva es de 7.8 años y 11.2 años, respectivamente.

Información clave

Alan Fang

Chief Executive Officer (CEO)

HK$60.0k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	7.8yrs
Participación del CEO	56.7%
Permanencia media de la dirección	7.8yrs
Promedio de permanencia en la Junta Directiva	11.2yrs

Actualizaciones recientes de la dirección

Recent updates

Lacklustre Performance Is Driving Tianda Pharmaceuticals Limited's (HKG:455) 25% Price Drop

Oct 28

Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Aug 16

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Jun 20

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Mar 27

CEO

Alan Fang (55 yo)

7.8yrs

Permanencia

HK$60,000

Compensación

Mr. Wen Quan Fang, also known as Alan, has been serves as Managing Director of Tianda Pharmaceuticals Limited since February 1, 2017. Mr. Fang has been Managing Director of Tianda Holdings Limited since Se...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Wen Quan Fang	Executive Chairman & MD	7.8yrs	HK$60.00k	56.72% HK$ 225.6m
Man Sang Lui	Executive Director	11.2yrs	HK$72.00k	sin datos
Man Yuk Wong	Financial Controller	4.8yrs	sin datos	sin datos
Tai On Lo	Company Secretary	no data	sin datos	sin datos

7.8yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 455 es experimentado (7.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Wen Quan Fang	Executive Chairman & MD	21.1yrs	HK$60.00k	56.72% HK$ 225.6m
Man Sang Lui	Executive Director	11.2yrs	HK$72.00k	sin datos
Sung Hong Chiu	Independent Non-Executive Director	16.6yrs	HK$72.00k	sin datos
Yat-Fai Lam	Independent Non-Executive Director	20.2yrs	HK$72.00k	sin datos
Tao Zhong	Non-Executive Director	1.3yrs	HK$25.00k	sin datos
Quanming Feng	Non-Executive Director	8.7yrs	sin datos	sin datos
Yanfang Xian	Independent Non-executive Director	1.4yrs	HK$37.00k	sin datos

11.2yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 455 son experimentados ( 11.2 años antigüedad media).

Tianda Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 07, 2024

Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023

Tianda Pharmaceuticals Limited Announces Board Changes

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2023

Executive Chairman & MD recently bought HK$2.7m worth of stock

Executive Chairman & MD recently bought HK$448k worth of stock

Recent updates

Lacklustre Performance Is Driving Tianda Pharmaceuticals Limited's (HKG:455) 25% Price Drop

First half 2024 earnings released

New major risk - Financial data availability

New major risk - Financial position

New minor risk - Share price stability

Tianda Pharmaceuticals Limited Provides Unaudited Consolidated Earnings Guidance for the Six-Month Period from 1 January 2024 to 30 June 2024

Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Tianda Pharmaceuticals Limited to Report First Half, 2024 Results on Aug 28, 2024

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd. Receives Drug Registration Approval of Ibuprofen Suspension

Tianda Pharmaceuticals Limited Approves Final Dividend

Now 24% overvalued after recent price rise

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 07, 2024

Now 21% overvalued after recent price rise

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

New major risk - Revenue and earnings growth

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023

Tianda Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Now 26% undervalued

Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Now 29% undervalued

Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Interim Period Ended June 30, 2023

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 28% undervalued

Tianda Pharmaceuticals Limited (SEHK:455) entered into an equity transfer agreement to acquire 45% stake in Yunnan Mengsheng Pharmaceutical Co., Ltd from Yunnan Linuo Biotechnology Co., Ltd. for HKD 23.5 million.

Tianda Pharmaceuticals Limited Announces Board Changes

Now 25% undervalued after recent price drop

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2023

Full year 2022 earnings released: HK$0.025 loss per share (vs HK$0.011 loss in FY 2021)

Executive Chairman & MD recently bought HK$2.7m worth of stock

Executive Chairman & MD recently bought HK$448k worth of stock

Executive Chairman & MD recently bought HK$52k worth of stock

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

First half 2023 earnings released: HK$0.008 loss per share (vs HK$0.008 loss in 1H 2022)

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 25, 2022

Less than half of directors are independent

Executive Chairman & MD recently bought HK$129k worth of stock

Tianda Pharmaceuticals Limited Declares Final Dividend

Tianda Pharmaceuticals Limited, Annual General Meeting, Aug 25, 2022

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended March 31, 2022, Payable on September 08, 2022

Full year 2022 earnings released

Tianda Pharmaceuticals Limited Proposes Special Dividend for the Year Ended 31 March 2022

Tianda Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Non-Executive Director Lee George Lam has left the company

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ended 31 March 2021

First half 2021 earnings released: HK$0.007 loss per share

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

First half 2021 earnings released: HK$0.007 loss per share

Tianda Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 27, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad